These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31536150)

  • 1. The role of adjuvant chemotherapy in stage II and III mucinous colon cancer.
    Fields AC; Lu P; Goldberg J; Irani J; Bleday R; Melnitchouk N
    J Surg Oncol; 2019 Dec; 120(7):1190-1200. PubMed ID: 31536150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis.
    Powers BD; Felder SI; Imanirad I; Dessureault S; Dineen SP
    J Gastrointest Cancer; 2021 Jun; 52(2):719-727. PubMed ID: 32743731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
    Asare EA; Compton CC; Hanna NN; Kosinski LA; Washington MK; Kakar S; Weiser MR; Overman MJ
    Cancer; 2016 Jan; 122(2):213-21. PubMed ID: 26506400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma.
    Yu D; Gao P; Song Y; Yang Y; Chen X; Sun Y; Li A; Wang Z
    Cancer Med; 2018 Mar; 7(3):600-615. PubMed ID: 29380562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal.
    Babcock BD; Aljehani MA; Jabo B; Choi AH; Morgan JW; Selleck MJ; Luca F; Raskin E; Reeves ME; Garberoglio CA; Lum SS; Senthil M
    Ann Surg Oncol; 2018 Jul; 25(7):1980-1985. PubMed ID: 29675762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Adjuvant Chemotherapy Following Right Hemicolectomy for Non-metastatic Mucinous and Nonmucinous Appendiceal Adenocarcinoma.
    AlMasri SS; Paniccia A; Hammad AY; Pai RK; Bahary N; Zureikat AH; Medich DS; Celebrezze JP; Choudry HA; Nassour I
    J Gastrointest Surg; 2022 Jan; 26(1):171-180. PubMed ID: 34291365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer.
    Catalano V; Loupakis F; Graziano F; Bisonni R; Torresi U; Vincenzi B; Mari D; Giordani P; Alessandroni P; Salvatore L; Fornaro L; Santini D; Baldelli AM; Rossi D; Giustini L; Silva RR; Falcone A; D'Emidio S; Rocchi M; Luzi Fedeli S
    Ann Oncol; 2012 Jan; 23(1):135-141. PubMed ID: 21531784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment.
    Ott C; Gerken M; Hirsch D; Fest P; Fichtner-Feigl S; Munker S; Schnoy E; Stroszczynski C; Vogelhuber M; Herr W; Evert M; Reng M; Schlitt HJ; Klinkhammer-Schalke M; Teufel A
    Digestion; 2018; 98(3):143-152. PubMed ID: 29870979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
    Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
    Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and survival benefit of adjuvant chemotherapy in stage III colon cancer patients: Comparison of overall and age-stratified results by multivariable modeling and propensity score methodology in a population-based cohort.
    Hines RB; Bimali M; Johnson AM; Bayakly AR; Collins TC
    Cancer Epidemiol; 2016 Oct; 44():77-83. PubMed ID: 27513721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor.
    Hugen N; Verhoeven RH; Lemmens VE; van Aart CJ; Elferink MA; Radema SA; Nagtegaal ID; de Wilt JH
    Int J Cancer; 2015 Jan; 136(2):333-9. PubMed ID: 24841868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy.
    Malik YG; Lyckander LG; Lindstrøm JC; Vinge-Holmquist O; Sheikh AE; Schultz JK; Ignjatovic D
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):61-71. PubMed ID: 32924067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
    Casadaban L; Rauscher G; Aklilu M; Villenes D; Freels S; Maker AV
    Cancer; 2016 Nov; 122(21):3277-3287. PubMed ID: 27417445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients.
    Birkett RT; Chamely E; Concors SJ; Bleier JI; Aarons CB; Shanmugan S; Saur NM; Paulson EC
    Clin Colorectal Cancer; 2019 Dec; 18(4):292-300. PubMed ID: 31447135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse effect of mucinous component on survival in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Yamamoto G; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(7):851-7. PubMed ID: 25111953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.